-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$39.3395.38% Upside
NewAmsterdam Pharma Company N.V. Frequently Asked Questions
-
What analysts cover NewAmsterdam Pharma Company N.V.?
NewAmsterdam Pharma Company N.V. has been rated by research analysts at Leerink Partners, Piper Sandler, Needham in the past 90 days.